TED Ted Baker Plc

RNS Number:5030Q
Tepnel Life Sciences PLC
01 February 2007



FOR IMMEDIATE RELEASE


               Tepnel Life Sciences plc ('Tepnel' or 'the Company')

 Tepnel grants exclusive license for Solid Phase Amplification (SPA) technology
                              to US-based company



Manchester, U.K., 1 February January 2007 Tepnel Life Sciences PLC (AIM: TED),
the international Molecular Diagnostics and Research Products & Services group,
announced today that it has granted exclusive licensing rights to its Solid
Phase Amplification (SPA) technology for use in the field of non-bead based
amplification prior to nucleic acid sequencing to a US-based company.  The SPA
technology, which was developed by Tepnel's Research Products and Services
Division, can be used in DNA sequencing systems.



Tepnel will receive an up front payment as well as ongoing annual royalties and
a shared split on sub-licensing monies.



Commenting on the licensing agreement, Ben Matzilevich, Tepnel CEO said, "Tepnel
is pleased to licence certain aspects of our nucleic acid amplification
technology. This technology has the potential to increase the capacity of DNA
sequencing automated systems. This agreement highlights the continued success of
our Research Products and Services business and the efforts of our research
staff."







                                     -End-



For Further Information:



Tepnel Life Sciences plc
Ben Matzilevich, CEO
Tel: 0161 946 2200



Capital MS&L
Mary Clark or Halina Kukula
Tel: +44 20 7307 5330
Email: mary.clark@capitalmsl.com



Notes to Editors

About Tepnel Life Sciences plc

Tepnel Life Sciences (AIM:TED) is a UK-based international life sciences
products and services group with two divisions, Molecular Diagnostics and
Research Products & Services. The Company has laboratories, manufacturing and
operations in the USA, UK and France with 195 employees.  TLS provides test
kits, reagents and services to two highly synergistic markets, these being
Molecular Diagnostics and Biomedical Research.  The company's strategy has been
to identify high growth niche opportunities within these multi-billion pound
markets.  TLS focuses on these niche opportunities with internally developed
products, patents, expertise and know-how as well as strategic acquisitions, to
develop a leadership position within these defined market segments.



SPA Technology

The traditional approach to gene analysis relies on using the polymerase chain
reaction (PCR) and involves the hybridisation of labelled probes to
free-floating DNA targets that are passively absorbed to solid supports such as
nitrocellulose. SPA technology differs from this by instead using surface-bound
DNA primers to limit amplification to two-dimensional surfaces. This enables
more rapid amplification of the DNA targets and is particularly valuable to the
DNA microchip industry for the large scale assays of genetic material.






                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

MSCSDSFWFSWSEFF

Ted Baker (LSE:TED)
Historical Stock Chart
From Jun 2024 to Jul 2024

Ted Baker (LSE:TED)
Historical Stock Chart
From Jul 2023 to Jul 2024